Existing biochemical markers are not suitable for assessing early myocardial ischemia
particularly in first 2-6 hours of ischemia ie before setting in of irreparable myocardial …

Introduction: Serum levels of ischemia-modified albumin (IMA) has recently been introduced
as an early marker of myocardial ischemia in management of patients with acute coronary …

Myocardial ischemia produces free radicals that catalyze a series of oxidative reactions that
damage healthy tissues. The N-terminal sequence of albumin is one of the proteins modified …

Early identification of patients with acute myocardial infarction is of prime importance due to
the associated very high mortality. Only 22% of the patients presenting at emergency …

Objectives: We investigated whether ischemia-modified albumin (IMA), a novel biomarker of
acute myocardial ischemia, is reliable for diagnosing ischemic chest pain and predicting …

Objective The diagnosis of coronary artery disease (CAD) is an important clinical problem.
Ischemia-modified albumin (IMA) has been demonstrated to be a helpful marker in detecting …

Abstract Background. Approximately 40–60% of patients with acute coronary syndrome
(ACS) have normal cardiac troponin I (cTnI) concentrations on admission. Ischaemia …

BACKGROUND: Ischemia-modified albumin (IMA) has been shown to be a rapidly rising
and sensitive biochemical marker for the diagnosis of myocardial ischemia. In this study, we …

Currently, there are no well-defined biochemical markers for identification of myocardial
ischemia in normolipidaemic AMI individuals. Biochemical markers such as CK-MB, cTnl …

The diagnosis of cardiac ischemia remains a challenge in contemporary emergency
medicine. A blood-borne biomarker is an attractive alternative to cardiac imaging or stress …